vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Virgin Galactic Holdings, Inc (SPCE). Click either name above to swap in a different company.
Virgin Galactic Holdings, Inc is the larger business by last-quarter revenue ($4.2M vs $3.9M, roughly 1.1× Citius Pharmaceuticals, Inc.). Citius Pharmaceuticals, Inc. runs the higher net margin — -238.2% vs -2222.2%, a 1984.0% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
Virgin Galactic Holdings, Inc. is a British-American spaceflight company founded by Richard Branson and the Virgin Group conglomerate, which retains an 11.9% stake through Virgin Investments Limited.
CTXR vs SPCE — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $4.2M |
| Net Profit | $-9.4M | $-93.8M |
| Gross Margin | 80.0% | -546.6% |
| Operating Margin | -228.7% | -2412.1% |
| Net Margin | -238.2% | -2222.2% |
| Revenue YoY | — | 125.5% |
| Net Profit YoY | 8.6% | 30.2% |
| EPS (diluted) | $-0.38 | $-4.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | — | ||
| Q2 24 | — | $4.2M | ||
| Q1 24 | — | $2.0M | ||
| Q4 23 | — | $2.8M | ||
| Q3 23 | — | $1.7M | ||
| Q2 23 | — | $1.9M | ||
| Q4 22 | — | $869.0K | ||
| Q3 22 | — | $767.0K |
| Q4 25 | $-9.4M | — | ||
| Q2 24 | — | $-93.8M | ||
| Q1 24 | — | $-102.0M | ||
| Q4 23 | — | $-104.0M | ||
| Q3 23 | — | $-104.6M | ||
| Q2 23 | — | $-134.4M | ||
| Q4 22 | — | $-150.8M | ||
| Q3 22 | — | $-145.6M |
| Q4 25 | 80.0% | — | ||
| Q2 24 | — | -546.6% | ||
| Q1 24 | — | -1038.1% | ||
| Q4 23 | — | -766.4% | ||
| Q3 23 | — | -1384.3% | ||
| Q2 23 | — | 87.5% | ||
| Q4 22 | — | -34.5% | ||
| Q3 22 | — | 23.1% |
| Q4 25 | -228.7% | — | ||
| Q2 24 | — | -2412.1% | ||
| Q1 24 | — | -5599.9% | ||
| Q4 23 | — | -4067.8% | ||
| Q3 23 | — | -6613.0% | ||
| Q2 23 | — | -7459.4% | ||
| Q4 22 | — | -17642.2% | ||
| Q3 22 | — | -18978.0% |
| Q4 25 | -238.2% | — | ||
| Q2 24 | — | -2222.2% | ||
| Q1 24 | — | -5139.1% | ||
| Q4 23 | — | -3701.8% | ||
| Q3 23 | — | -6053.5% | ||
| Q2 23 | — | -7181.4% | ||
| Q4 22 | — | -17355.6% | ||
| Q3 22 | — | -18977.1% |
| Q4 25 | $-0.38 | — | ||
| Q2 24 | — | $-4.36 | ||
| Q1 24 | — | $-5.10 | ||
| Q4 23 | — | $-14.49 | ||
| Q3 23 | — | $-5.57 | ||
| Q2 23 | — | $-9.16 | ||
| Q4 22 | — | $-0.55 | ||
| Q3 22 | — | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $775.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $394.8M |
| Total Assets | $140.4M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | — | ||
| Q2 24 | — | $775.7M | ||
| Q1 24 | — | $765.2M | ||
| Q4 23 | — | $874.0M | ||
| Q3 23 | — | $997.1M | ||
| Q2 23 | — | $940.2M | ||
| Q4 22 | — | $909.0M | ||
| Q3 22 | — | $1.0B |
| Q4 25 | $80.0M | — | ||
| Q2 24 | — | $394.8M | ||
| Q1 24 | — | $417.6M | ||
| Q4 23 | — | $505.5M | ||
| Q3 23 | — | $599.4M | ||
| Q2 23 | — | $484.5M | ||
| Q4 22 | — | $480.2M | ||
| Q3 22 | — | $613.5M |
| Q4 25 | $140.4M | — | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B | ||
| Q4 23 | — | $1.2B | ||
| Q3 23 | — | $1.3B | ||
| Q2 23 | — | $1.1B | ||
| Q4 22 | — | $1.1B | ||
| Q3 22 | — | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-79.1M |
| Free Cash FlowOCF − Capex | — | $-113.5M |
| FCF MarginFCF / Revenue | — | -2690.7% |
| Capex IntensityCapex / Revenue | — | 815.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-458.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | — | ||
| Q2 24 | — | $-79.1M | ||
| Q1 24 | — | $-113.2M | ||
| Q4 23 | — | $-95.3M | ||
| Q3 23 | — | $-91.5M | ||
| Q2 23 | — | $-125.3M | ||
| Q4 22 | — | $-131.2M | ||
| Q3 22 | — | $-96.0M |
| Q4 25 | — | — | ||
| Q2 24 | — | $-113.5M | ||
| Q1 24 | — | $-126.3M | ||
| Q4 23 | — | $-113.7M | ||
| Q3 23 | — | $-104.8M | ||
| Q2 23 | — | $-135.2M | ||
| Q4 22 | — | $-135.4M | ||
| Q3 22 | — | $-102.1M |
| Q4 25 | — | — | ||
| Q2 24 | — | -2690.7% | ||
| Q1 24 | — | -6362.8% | ||
| Q4 23 | — | -4046.9% | ||
| Q3 23 | — | -6066.1% | ||
| Q2 23 | — | -7224.3% | ||
| Q4 22 | — | -15584.0% | ||
| Q3 22 | — | -13305.2% |
| Q4 25 | — | — | ||
| Q2 24 | — | 815.5% | ||
| Q1 24 | — | 658.5% | ||
| Q4 23 | — | 653.9% | ||
| Q3 23 | — | 771.1% | ||
| Q2 23 | — | 526.4% | ||
| Q4 22 | — | 481.4% | ||
| Q3 22 | — | 784.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
